Add on Interferon-Alpha-2a for the Treatment of HBeAg Negative Hepatitis B Patients Receiving Effective Nucleos(t)ide Therapy: Interim Results of the Prospective Multicentre PADD-On Trial

The role of peginterferon in nucleos(t)ide‐analogue‐treated chronic hepatitis B patients: A review of published literature

“…Half of all patients achieved undetectable HBV‐DNA, but decline in HBsAg was modest, particularly in those who did not achieve durable response after treatment discontinuation . Add‐on strategies for HBeAg‐negative patients have since been further investigated in three recent large multicentre trials …”

“…The ongoing multicentre randomized PADD‐ON study is investigating the effect of add‐on PegIFN in 137 patients who have achieved virological suppression with a previous NA . Interim 24‐week results showed that significantly more patients achieved HBsAg decline ≥10% with add‐on PegIFN compared with NA monotherapy (71% vs 37%; P =.0006) …”

“…32 Add-on strategies for HBeAg-negative patients have since been further investigated in three recent large multicentre trials. [33][34][35] In the PEGAN study, which enrolled a large number of patients (N=183), HBsAg loss and seroconversion rates with add-on PegIFN were 8% and 7%, respectively, at EOT and only 3% and 1%, respectively, in those who remained on NA monotherapy. 33 In the single-arm HERMES study, genotype D NA-treated patients with sustained HBV-DNA suppression (<20 IU/mL) received add-on PegIFN for 48 weeks and were followed up for an additional 48 weeks.…”